Individualización del tratamiento en Adenocarcinoma de pulmón tras la primera línea de quimioterapia

Anti-PD1 and anti-PDL1 therapies in previously

treated advanced NSCLC: trial design

Brahmer, et al. N Engl J Med 2015 373(2): 123–35; Borghaei, et al. N Engl J Med 2015 373(17): 1627–39

Herbst, et al. Lancet 2016 387(10027): 1540–50; Barlesi, et al. ESMO 2016 (Abs.LBA44)

NSCLC Stage IV (2L/3L)

1. Nivolumab

SqCC

N=272

2. Nivolumab

NSq

N=582

3. Pembrolizumab

>1%

N=1024

4. Atezolizumab

Any

N=1225

Docetaxel

Checkpoint

inhibitor

1:1